Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ETH52
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Ethris
Deal Size : Undisclosed
Deal Type : Collaboration
Ethris And Lonza Team Up For Spray-Dried mRNA Respiratory Vaccines
Details : The initial focus of the collaboration is to develop a first-in-class mRNA vaccine candidate against influenza delivered nasally.
Product Name : ETH52
Product Type : Vaccine
Upfront Cash : Undisclosed
April 07, 2025
Lead Product(s) : ETH52
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Ethris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Exo-101
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Exogenus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Exogenus Therapeutics Partners with Lonza to Develop GMP Process for Exo-101 Manufacturing
Details : The collaboration aims to develop Exo-101, Exogenus’ exosome-based lead candidate. It is derived from immunologically privileged cells from umbilical cord blood, being evaluating for fibrosis.
Product Name : Exo-101
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Exo-101
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Exogenus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY
Details : Under the terms of the agreement, Vertex will leverage Lonza’s scientific, regulatory and manufacturing expertise for manufacturing of Casgevy (exagamglogene autotemcel).
Product Name : Casgevy
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VX-880
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
Details : The collaboration aims to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, focusing on the VX-880 (STx-02) and VX-264 programs in clinic...
Product Name : VX-880
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : VX-880
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : W0180,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Agreement
Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product
Details : The collaboration is aimed to manufacture W0180, an innovative monoclonal antibody discovered by Pierre Fabre targeting the VISTA checkpoint, currently being investigated as a single agent and in combination with pembrolizumab in Phase I clinical trial i...
Product Name : W0180
Product Type : Antibody
Upfront Cash : Undisclosed
June 15, 2022
Lead Product(s) : W0180,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Agreement
Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil
Details : Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufactur...
Product Name : TRX-E-002-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 21, 2022
Lead Product(s) : LEU011
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Leucid Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralized manufacturing model including its lead product, LEU-0...
Product Name : LEU011
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 02, 2021
Lead Product(s) : LEU011
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Leucid Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TAC01-HER2,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
Details : Triumvira’s TAC01-HER2 was manufactured using Lonza’s Cocoon® Platform, a state-of-the-art, automated and self-contained manufacturing system that offers an elegant solution to address many of the challenges of manufacturing autologous cell therapie...
Product Name : TAC01-HER2
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 20, 2021
Lead Product(s) : TAC01-HER2,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : CellPoint
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : CellPoint
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will help Gracell leverage Lonza's worldwide integrated services and expertise in CAR-T cell therapy manufacturing. Gracell is advancing its innovative CAR-T pipeline globally for difficult-to-treat cancers, including its lead program f...
Product Name : GC012F
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 31, 2021